The Synergy of Early Detection and KRAS Inhibition in Pancreatic Cancer

The advancement of pancreatic cancer treatment requires a dual-track approach that prioritizes both early detection and therapeutic innovation, said Diane Simeone, MD. During an interview regarding recent findings with daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC), Simeone emphasized that investments in these areas must happen in parallel to significantly improve patient outcomes. The aforementioned results with daraxonrasib came from the phase 3 RASolute 302 trial (NCT06625320), which demonstrated a near doubling of overall survival, with a median OS of 13.2 months with daraxonrasib vs 6.7 months with standard of care.¹

Currently, funding for early detection and prevention accounts for only 6% to 8% of all cancer research investments, an imbalance that limits the ability to identify the disease at its most treatable stages.

The clinical significance of early intervention is substantial; Simeone noted that if stage I pancreatic cancer is identified and resected, the cure rate is at least 83%. A cornerstone of this effort is the PRECEDE (NCT04970056) consortium, which represents the world’s largest longitudinal study for individuals at high risk for pancreatic cancer.² With approximately 12,000 individuals enrolled across 65 centers globally, PRECEDE serves as a platform to identify and validate the most effective early detection tools. The goal is to move toward the broad dissemination of these tools, facilitating the downstaging of tumors for more patients with cancer.

Simeone highlighted the transformative potential of combining early diagnosis with precision medicine, such as KRAS inhibition. For patients diagnosed with stage II disease, the current survival rate is approximately 40%. However, a strategy involving surgical resection followed by a short course of treatment with a KRAS inhibitor could potentially increase the survival rate to 90%. By ensuring that screening initiatives and drug advances occur concomitantly, the oncology community can transition from managing advanced disease to achieving highly curative outcomes. This synergistic strategy remains essential for improving long-term survival for patients with this recalcitrant malignancy.

Simeone is the director of the Moores Cancer Center at UC San Diego Health.

Transcript:

The investments need to happen in parallel. We’ve talked before about the fact that only 6% to 8% of all cancer funding is on early detection and prevention, and we’ve also talked about the fact that if we can find early stage I pancreas cancers and resect them, the cure rate is at least 83%. I think the downstaging of cancers and better understanding who’s at risk [are important]. With PRECEDE, we have the world’s largest longitudinal study of people at high risk for pancreas cancer—about 12,000 individuals at 65 centers worldwide. That’s a platform to figure out which early detection tools work the best and then see where we can have an opportunity to disseminate those early detection tools more broadly. If I can find a stage I cancer, it might be that it doesn’t need any treatment, and that’s the best option. But if we find a stage II cancer and resect it, then we can do a follow-up short treatment with a KRAS inhibitor. That could also become a very highly curative situation, where we go from a 40% survival [rate] with stage II [disease] to a 90% survival [rate]. Those 2 things sprinting in parallel—that’s what we need for this disease.

References

1. Daraxonrasib demonstrates unprecedented overall survival benefit in pivotal phase 3 RASolute 302 clinical trial in patients with metastatic pancreatic cancer. News release. Revolution Medicines Inc. April 13, 2026. Accessed April 21, 2026. https://tinyurl.com/44t5vh5d
2. Pancreatic Cancer Early Detection Consortium (PRECEDE). ClinicalTrials.gov. Updated January 28. 2026. Accessed April 21, 2026. https://tinyurl.com/mwtxk2nj